

Comparative segment information

Invoicing EUR million	2026 1-6	2026 1-3	2025 1-12	2025 1-9	2025 1-6	2025 1-3	2024 1-12
Services	2,182.4	1,068.0	4,146.0	3,049.6	2,044.1	984.6	3,707.1
Products*	32.3	15.4	66.4	50.6	35.1	20.0	79.6
Invoicing between segments	-4.4	-2.2	-11.2	-8.8	-6.5	-4.4	-14.9
Total	2,210.2	1,081.2	4,201.2	3,091.4	2,072.8	1,000.2	3,771.8

*Including dose dispensing Sweden - - 6.0 6.0 6.0 6.0 21.7

Net sales EUR million	2026 1-6	2026 1-3	2025 1-12	2025 1-9	2025 1-6	2025 1-3	2024 1-12
Services	73.7	36.6	146.5	108.3	73.2	35.3	135.1
Products*	32.3	15.4	66.3	50.5	35.1	20.0	79.8
Net sales between segments**	-0.1	-0.1	-2.5	-2.4	-2.4	-2.3	-7.7
Total	105.9	51.9	210.4	156.4	105.9	52.9	207.2

*Including dose dispensing Sweden - - 6.0 6.0 6.0 6.0 21.7

**impacted by the restatement in Q3/2026

Adjusted EBITDA EUR million	2026 1-6	2026 1-3	2025 1-12	2025 1-9	2025 1-6	2025 1-3	2024 1-12
Services	17.1	8.0	37.3	27.3	17.7	8.5	34.6
Products*	3.1	2.1	5.7	4.0	2.2	1.0	5.5
Group administration and others	-4.5	-2.5	-7.9	-6.1	-4.3	-2.0	-6.7
Total	15.7	7.7	35.1	25.2	15.6	7.5	33.4

*Including dose dispensing Sweden - - 0.2 0.2 0.2 0.2 0.1

EBITDA EUR million	2026 1-6	2026 1-3	2025 1-12	2025 1-9	2025 1-6	2025 1-3	2024 1-12
Services	16.7	8.0	35.4	26.1	17.4	8.4	34.5
Products*	3.1	2.1	2.9	1.3	-0.6	1.0	6.0
Group administration and others	-10.7	-4.9	-18.0	-12.9	-9.3	-3.5	-13.3
Total	9.1	5.3	20.3	14.5	7.5	6.0	27.2

*Including dose dispensing Sweden - - -2.5 -2.6 -2.6 0.2 1.6

Adjusting items EUR million	2026 1-6	2026 1-3	2025 1-12	2025 1-9	2025 1-6	2025 1-3	2024 1-12
Services	0.4	0.0	1.9	1.2	0.3	0.1	0.1
Products*	0.0	0.0	2.8	2.8	2.8	0.0	-0.5
Group administration and others	6.2	2.4	10.1	6.7	5.0	1.5	6.7
Total	6.6	2.4	14.8	10.7	8.1	1.6	6.2

*Including dose dispensing Sweden - - 2.8 2.8 2.8 0.0 -1.4

Number of personnel at the end of the period	2026 1-6	2026 1-3	2025 1-12	2025 1-9	2025 1-6	2025 1-3	2024 1-12
Services	571	590	591	593	604	595	572
Products*	150	137	134	133	129	176	172
Group administration and others	74	73	76	76	75	74	72
Total	796	800	801	801	808	845	816

*Including dose dispensing Sweden - - - - - 54 49

Average number of personnel, full time equivalents	2026 1-6	2026 1-3	2025 1-12	2025 1-9	2025 1-6	2025 1-3	2024 1-12
Services	573	593	593	596	587	567	562
Products*	139	135	140	142	147	171	176
Group administration and others	88	72	80	82	85	95	74
Total	800	801	813	819	819	834	812

*Including dose dispensing Sweden - - 12 16 24 49 48

Quarterly invoicing EUR million	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Services	1,114.4	1,068.0	1,096.4	1,005.5	1,059.5	984.6	966.6	911.1	936.2	893.1
Products	16.9	15.4	15.8	15.4	15.2	20.0	21.1	20.6	19.6	18.3
Invoicing between segments	-2.2	-2.2	-2.5	-2.3	-2.1	-4.4	-4.2	-4.0	-3.6	-3.1
Total	1,129.1	1,081.2	1,109.8	1,018.6	1,072.6	1,000.2	983.5	927.7	952.2	908.4

*Including dose dispensing Sweden - - 0.0 0.0 0.1 6.0 6.2 5.8 5.3 4.4

Quarterly net sales EUR million	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Services	37.1	36.6	38.2	35.1	37.9	35.3	35.6	31.5	33.7	34.3
Products	16.9	15.4	15.8	15.4	15.2	20.0	21.4	20.5	19.6	18.3
Net sales between segments**	-0.1	-0.1	-0.1	0.0	-0.1	-2.3	-2.2	-2.0	-2.0	-1.5
Total	53.9	51.9	54.0	50.4	53.0	52.9	54.7	50.0	51.3	51.1

*Including dose dispensing Sweden - - 0.0 0.0 0.1 6.0 6.2 5.8 5.3 4.4

**impacted by the restatement in Q3/2026

Quarterly adjusted EBITDA EUR million	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Services	9.0	8.0	10.0	9.6	9.3	8.5	9.5	8.4	7.7	9.0
Products	1.0	2.1	1.6	1.9	1.1	1.0	1.3	1.8	1.5	0.9
Group administration and others	-1.9	-2.5	-1.8	-1.8	-2.3	-2.0	-1.4	-1.8	-1.1	-2.2
Total	8.1	7.7	9.9	9.6	8.1	7.5	9.4	8.4	8.0	7.7

*Including dose dispensing Sweden - - 0.0 0.0 0.2 0.3 0.1 0.2 -0.5 -0.5

Quarterly EBITDA EUR million	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Services	8.7	8.0	9.3	8.7	9.0	8.4	9.5	8.4	7.7	8.9
Products	1.0	2.1	1.6	1.9	-1.7	1.0	1.3	0.9	2.9	0.9
Group administration and others	-5.8	-4.9	-5.2	-3.6	-5.8	-3.5	-3.8	-4.4	-2.0	-3.1
Total	3.9	5.3	5.8	7.0	1.6	6.0	7.0	4.9	8.6	6.7

*Including dose dispensing Sweden - - 0.0 0.0 -2.8 0.2 0.3 0.1 1.7 -0.5

Non-current assets ¹	2026	2026	2025	2025	2025	2025	2024	2024	2024	2024
EUR million	30 Jun	31 Mar	31 Dec	30 Sep	30 Jun	31 Mar	31 Dec	30 Sep	30 Jun	31 Mar
Services	70.0	70.4	72.2	72.2	73.1	75.5	61.9	59.3	60.2	61.0
Products	6.1	6.3	6.6	6.7	6.9	7.2	18.5	16.1	16.6	16.8
Group administration and others	207.0	208.5	207.4	227.9	228.9	231.6	232.4	252.6	256.4	258.2
Total	283.0	285.3	286.2	306.7	308.9	314.3	312.8	328.0	333.2	336.0

¹ Non-current assets exclude financial instruments and deferred tax assets.

Quarterly investments	2026	2026	2025	2025	2025	2025	2024	2024	2024	2024
EUR million	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Services	2.1	0.6	1.4	0.8	0.5	0.2	1.0	0.3	0.3	0.4
Products	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	0.0
Group administration and others	0.2	4.7	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0
Total	2.3	5.3	1.6	0.8	0.5	0.3	1.7	0.3	0.4	0.4

Depreciation, amortisation and impairments, EUR million	2026	2026	2025	2025	2025	2025	2024	2024	2024	2024
	1-6	1-3	1-12	1-9	1-6	1-3	1-12	1-9	1-6	1-3
Services	5.5	2.8	10.2	7.6	5.1	2.5	10.1	7.6	5.1	2.6
Products	1.0	0.5	7.4	7.0	6.6	6.1	1.5	1.1	0.7	0.4
Group administration and others	0.1	0.0	0.2	0.1	0.1	0.0	2.0	1.9	0.1	0.0
Total	6.6	3.4	17.7	14.7	11.8	8.7	13.6	10.6	5.9	3.0